Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.61 |
| ▸ | CA1 | P00915 | 6/20 | 0.61 |
| ▸ | CA2 | P00918 | 6/20 | 0.61 |
| ▸ | CA9 | Q16790 | 6/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 6/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4138078 | 0.98 | CA12 (0.62) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL759464 | 0.95 | CA12 (0.55) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL757089 | 0.89 | TDP1 (0.47) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL28006307 | 0.86 | CA1 (0.46) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL13405231 | 0.84 | TSHR (0.56) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL9966901 | 0.84 | TSHR (0.56) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL18352554 | 0.83 | CA12 (0.57) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL18353026 | 0.82 | CA12 (0.58) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL16450357 | 0.82 | CA12 (0.54) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL19636118 | 0.82 | TSHR (0.46) | CA12CA1CA2CA9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10022456-B2 | Reversibly masked polymers | Arrowhead Pharmaceuticals, Inc. (US) | 2018-07-17 | — | — | US | disclosed |
| US-10022456-B2 | Reversibly masked polymers | Arrowhead Pharmaceuticals, Inc. (US) | 2018-07-17 | — | — | US | disclosed |
| US-9452221-B2 | Poly(acrylate) polymers for in vivo nucleic acid delivery | Arrowhead Pharmaceuticals, Inc. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150273081-A1 | Reversibly Masked Polymers | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2015-10-01 | — | — | US | disclosed |
| US-20150273081-A1 | Reversibly Masked Polymers | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2015-10-01 | — | — | US | disclosed |
| US-20150104408-A1 | Poly(acrylate) Polymers for In Vivo Nucleic Acid Delivery | Arrowhead Madison Inc. (US) | 2015-04-16 | — | — | US | disclosed |
| US-8933047-B2 | Poly(acrylate) polymers for in vivo nucleic acid delivery | Arrowhead Madison Inc. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8541548-B2 | Delivering nucleic acids to cells; complexing nucleic acid with polyampholte; contacting cell; biocompatible in vivo delivery; gene therapy | Arrowhead Madison Inc. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541548-B2 | Delivering nucleic acids to cells; complexing nucleic acid with polyampholte; contacting cell; biocompatible in vivo delivery; gene therapy | Arrowhead Madison Inc. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8138383-B2 | For cellular delivery; heterogeneity polymer containing cationic groups and hydrophobic groups | Arrowhead Madison Inc. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20080287630-A1 | Endosomolytic Poly(Acrylate) Polymers | Arrowhead Pharmaceuticals, Inc. | 2008-11-20 | — | — | US | disclosed |
| US-20080287630-A1 | Endosomolytic Poly(Acrylate) Polymers | Arrowhead Pharmaceuticals, Inc. | 2008-11-20 | — | — | US | disclosed |
| US-20080281044-A1 | Endosomolytic Modified Poly(Alcohol) and Poly(Amine) Polymers | ROCHE MADISON INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080281044-A1 | Endosomolytic Modified Poly(Alcohol) and Poly(Amine) Polymers | ROCHE MADISON INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080281074-A1 | Compounds and Methods for Reversible Modification of Biologically Active Molecules | Arrowhead Madison Inc. | 2008-11-13 | — | — | US | disclosed |
| US-20080281074-A1 | Compounds and Methods for Reversible Modification of Biologically Active Molecules | Arrowhead Madison Inc. | 2008-11-13 | — | — | US | disclosed |
| US-20080281041-A1 | Reverse deactivation of membrane active polymers; cell delivery; labile bonding of polyamines, polyvinyl alcohol, polyallylamine or polyoxyethylene glycol | Arrowhead Madison Inc. | 2008-11-13 | — | — | US | disclosed |
| US-20080281041-A1 | Reverse deactivation of membrane active polymers; cell delivery; labile bonding of polyamines, polyvinyl alcohol, polyallylamine or polyoxyethylene glycol | Arrowhead Madison Inc. | 2008-11-13 | — | — | US | disclosed |
| US-20080269450-A1 | Endosomolytic Poly-Beta-Aminoester Polymers | ROCHE MADISON INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080269450-A1 | Endosomolytic Poly-Beta-Aminoester Polymers | ROCHE MADISON INC. | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150273081-A1 | Reversibly Masked Polymers | CD47, MSN, EPCAM | CA12 2322/4885CA1 3630/4885CA2 4064/4885 |
| US-10022456-B2 | Reversibly masked polymers | CD47, MSN, EPCAM | CA12 2322/4885CA1 3630/4885CA2 4064/4885 |
| US-20080281074-A1 | Compounds and Methods for Reversible Modification of Biologically Active Molecules | HDAC6, CD47, AADAC | CA12 1322/4885CA1 3569/4885CA2 3245/4885 |
| US-20150104408-A1 | Poly(acrylate) Polymers for In Vivo Nucleic Acid Delivery | PHAX, PARN, PARG | CA12 4530/4885CA1 4695/4885CA2 4478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.